Vertex Pharmaceuticals Incorporated (VRTX)
| Previous Close | 461.71 |
| Open | 465.00 |
| Bid | 461.85 x 100 |
| Ask | 463.89 x 100 |
| Day's Range | 459.07 - 465.83 |
| 52 Week Range | 346.29 - 519.88 |
| Volume | |
| Avg. Volume | 1,148,864 |
| Market Cap | 119.228B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.89 |
| Earnings Date | Feb 03, 2025 - Feb 07, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 514.80 |
Simply Wall St.Vertex Pharmaceuticals (NASDAQ:VRTX) shareholders are still up 137% over 3 years despite pulling back 3.4% in the past week
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...
Motley FoolDown 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. After all, it's been less than a year since regulators in the U.S. and E.U. approved its first therapy, Casgevy, to treat two blood-based disorders. Casgevy's initial launch hasn't been as exciting as investors and its partner, Vertex Pharmaceuticals (NASDAQ: VRTX), had hoped.
Motley Fool3 Monster Stocks in the Making
Here's why they think biotech stocks CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX) could become much larger. David Jagielski (CRISPR Therapeutics): If you're looking for stocks with mammoth upside, you might be tempted to look for risky stocks that don't have any approved drugs or treatments yet. In December 2023, regulators approved Casgevy, which is a gene-editing therapy the company has been developing with Vertex Pharmaceuticals.
